Latest articles
LLY Eli Lilly Stock Gains On Bofa’S Price Target Raise
Oct. 6, 2023, 12:49 p.m.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
LLYDay performance
| LLY | |
|---|---|
| Price | 601.10 |
| Change Pct | 1.01 |
| Change Abs | 6.01 |
| Market Cap | 570.6 billion |
| Eps | 5.53 |
| Pe Ratio | 108.70 |
| Outstanding Shares | 949.3 million |
| Volume | 1.3 million |
| Avg Volume | 3.2 million |
| Industry | Drug Manufacturers—General |
| Sector Name | Health Care |
| Country Short Name | null |
| Announcement Earnings | 2024-02-06 00:00:00+00:00 |
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
MRK
ABBV
JNJ
3 Login now
4 Login now
5 Login now
6 Login now
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
LLY
Company descriptions
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma;